tirzepatide 10mg pen Mounjaro 10 mg/0.5 mL pre-filled single-dose Images MOUNJARO KWIKPEN Tirzepatide 10mg /

Semaglutide targets one pathway

Mounjaro is approved by the FDA for managing type 2 diabetes in adults, while Zepbound is designed for chronic weight management

We only work with FDA-registered 503B outsourcing facilities that meet the highest standards for sterility, potency, and quality

Start your protocol Begin treatment in-clinic or at home (if eligible)

Tiredness, swelling/redness/itching at the injection site, loss of appetite, vomiting, nausea, upset stomach, constipation, and diarrhea are possible side effects of Zepbound

Referral to a registered dietitian for medical nutrition therapy can help identify dietary patterns that may be limiting weight loss